Disease progression patterns of bevacizumab responders with recurrent malignant gliomas

Tumor progression in patients with recurrent malignant glioma who respond to bevacizumab (BEV) is difficult to assess. The current study reviewed the clinical and radiological results of patients following a BEV-based chemotherapy regimen, and evaluated disease progression patterns in patients who r...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncol Lett
Asıl Yazarlar: Kim, Ju-Hwi, Jung, Tae-Young, Hwang, Eu Chang, Jung, Sung-Hoon, Jung, Shin, Kim, In-Young, Jang, Woo-Youl, Moon, Kyung-Sub, Lee, Kyung-Hwa, Kim, Seul-Kee
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: D.A. Spandidos 2017
Konular:
Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5588053/
https://ncbi.nlm.nih.gov/pubmed/28927109
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2017.6630
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller